Phase 1, Open Label, Multi-Center Study To Evaluate The Safety And Tolerability of CT-322 Administered In Combination With Focal Brain Radiotherapy And Temozolomide To Subjects With Newly Diagnosed Glioblastoma Multiforme.

Trial Profile

Phase 1, Open Label, Multi-Center Study To Evaluate The Safety And Tolerability of CT-322 Administered In Combination With Focal Brain Radiotherapy And Temozolomide To Subjects With Newly Diagnosed Glioblastoma Multiforme.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Oct 2010

At a glance

  • Drugs Pegdinetanib; Temozolomide
  • Indications Glioblastoma
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 26 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 03 Mar 2010 Planned number of patients changed from 50 to 30 as reported by ClinicalTrials.gov.
    • 17 Feb 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top